All Releases
Apr 12, 2016
- Company Will Host Conference Call on Wednesday, April 13 th , 8:30am EDT - - Guest Speaker Invited to Discuss REMOXY's Target Market - AUSTIN, Texas, April 12, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that the U.S.
Sep 21, 2015
AUSTIN, Texas, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported that the National Institutes of Health (NIH) has awarded the Company a $1.7 million innovation grant. This grant award provides a path forward for the Company to develop a small molecule drug,
Jul 23, 2015

Company is Focused on REMOXY NDA Resubmission, Targeted for Q1 2016

May 12, 2015
REMOXY Meets Both Primary Endpoints with Statistical Significance ( p < 0.0001) AUSTIN, Texas, May 12, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc., (Nasdaq:PTIE) today announced top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its
May 11, 2015

Conference Call Tomorrow, Tuesday, at 4:30 p.m. Eastern Time

May 07, 2015
- REMOXY ® Transition Nears Completion, Setting Stage for Eventual NDA Resubmission - AUSTIN, Texas, May 7, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the quarter ended March 31, 2015. Net loss in Q1 2015 was $2.6 million, or $0.06 per
Apr 23, 2015
AUSTIN, Texas, April 23, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a clinical-stage biopharmaceutical company, announced the appointment of Michael Marsman, Pharm.D., as Senior Vice President, Regulatory Affairs. Dr. Marsman will be responsible for developing and implementing